INCB-28060 FREE BASE |
INCB-28060 |
NYP-INC280-NX |
INC-280 |
NVP-INC280 |
CAPMATINIB |
NVP-INC280-NX |
INC280 |
TABRECTA |
INCB28060 |
chemidplus:1029712-80-8 |
pubchem.compound:25145656 |
drugbank:11791 |
chembl:CHEMBL3188267 |
Drug Class | Kinase Inhibitors |
Pharmaceutical Developer | Novartis |
Source Reported Drug Name(s) | INC280 |
Drug Class | MET Inhibitor |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Categories | acids, carbocyclic |
Drug Categories | amides |
Drug Categories | antineoplastic agents |
Drug Categories | bcrp/abcg2 inhibitors |
Drug Categories | benzene derivatives |
Drug Categories | benzoates |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | mate 1 inhibitors |
Drug Categories | mate 2 inhibitors |
Drug Categories | mate inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
Indication/Tumor Type | lung large cell carcinoma |
Response Type | sensitive |
INCB028060 | Development Name |
INC280 | Development Name |
Drug Class | Kinase Inhibitors |
INC280 | Drug Trade Name |
INC280 | Drug Development Name |
Drug Class | MET Inhibitor |
Source Reported Drug Name(s) | INC280 |
Pharmaceutical Developer | Novartis |
CAPMATINIB | DrugBank Drug Name |
1029712-80-8 | CAS Number |
Tabrecta | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
D07OJZ | TTD Drug ID |
INCB28060 | Primary Drug Name |
INCB28060 | Drug Synonym |
CAPMATINIB | GuideToPharmacology Ligand Name |